NEWS

  • TOP SCIENTISTS TO RECEIVE PRESTIGIOUS AWARDS FROM THE AMERICAN SOCIETY OF HEMATOLOGY

    Published: December 12, 2007PRNewswire-USNewswire Atlanta, Dec. 5 — The American Society of Hematology (ASH), the world’s largest professional society of blood specialists, is honoring three scientists who have made notable contributions to the genetic understanding of disease. Carlo Croce, MD, will receive the Henry M. Stratton Medal, intended to honor an individual with a distinguished… Read More »TOP SCIENTISTS TO RECEIVE PRESTIGIOUS AWARDS FROM THE AMERICAN SOCIETY OF HEMATOLOGY

    READ MORE

    EXELIXIS REPORTS DATA FROM ONGOING PHASE 1 STUDY OF XL019 TO TREAT MYELOFIBROSIS – UPDATE

    12/10/2007 2:06:40 PM Monday afternoon, Exelixis, Inc. (EXEL), a developer of therapies for the treatment of cancer and other serious diseases, announced data from an ongoing Phase 1 trial of XL019 to treat patients with myelofibrosis, a myeloproliferative disorder, or MPD. The primary objective of the trial is to determine the safety and tolerability of… Read More »EXELIXIS REPORTS DATA FROM ONGOING PHASE 1 STUDY OF XL019 TO TREAT MYELOFIBROSIS – UPDATE

    READ MORE

    GENE MUTATION PREDICTS OUTCOME IN BLOOD DISORDER

    Sunday December 10, 2007 8:00 am ET ORLANDO, Fla., Dec. 10 /PRNewswire/ — Both the cause and cure for polycythemia vera, a disorder of uncontrolled blood cell production, remain elusive, but researchers from the University of Florence, Italy, may be a step closer to both. Their findings are being presented today during the 48th Annual… Read More »GENE MUTATION PREDICTS OUTCOME IN BLOOD DISORDER

    READ MORE

    NOVARTIS ENTERS INTO PARTNERSHIP WITH INCYTE

    Novartis will collaborate with Incyte on the further development of two of Incyte Corp.’s compounds including the JAK2 Inhibitor INCB18424 currently in Phase III of the clinical trials process. If approved, this will be the first FDA approved treatment for myelfibrosis. For more information: Press release BioWorld

    READ MORE

    EXELIXIS WINNING PHASE I RACE

    By Mike Nagle 24/05/2007 – At a time when pharma productivity is declining, anticancer specialists Exelixis has started more Phase I clinical trials this year than any other company. The US biotech has today filed an Investigational New Drug (IND) application to US regulators at the Food and Drug Administration (FDA). It is the company’s… Read More »EXELIXIS WINNING PHASE I RACE

    READ MORE

    RESEARCHERS ADVANCING BLOOD CANCER THERAPIES RECEIVE $42.75 MILLION IN GRANTS FROM THE LEUKEMIA & LYMPHOMA SOCIETY

    Society’s Prestigious Specialized Center of Research Program Hits $159 Million Mark WHITE PLAINS, N.Y., Oct. 23 /PRNewswire/ — The Leukemia & Lymphoma Society today announced it has awarded four new Specialized Center of Research (SCOR) grants, the Society’s most ambitious and synergistic research initiative, bringing the program’s total funding to $159 million since its inception… Read More »RESEARCHERS ADVANCING BLOOD CANCER THERAPIES RECEIVE $42.75 MILLION IN GRANTS FROM THE LEUKEMIA & LYMPHOMA SOCIETY

    READ MORE

    UNIVERSITY OF UTAH TO INVESTIGATE BLOOD DISORDERS

    By Lois M. CollinsDeseret Morning News The University of Utah will receive more than $2 million over five years to investigate the causes of several incurable blood disorders. The money is part of a $19.6 million grant from the National Cancer Institute to the Myeloproliferative Disorders Research Consortium, a group of researchers from eight institutions… Read More »UNIVERSITY OF UTAH TO INVESTIGATE BLOOD DISORDERS

    READ MORE

    DISCOVERY OF A NEW MUTATION IN JAK2V617F NEGATIVE MYELOFIBROSIS PATIENTS

    By: Dr. Gary Gilliland, Harvard Medical School Many patients with polycythemia vera (PV), essential thrombocythemia (ET) or myelofibrosis (MF) have the JAK2V617F mutation. This finding has reinvigorated and revolutionized research on these MPDs. We now understand that there is a cell growth pathway that is activated by the JAK2V617F mutations, call the JAK-STAT pathway. This… Read More »DISCOVERY OF A NEW MUTATION IN JAK2V617F NEGATIVE MYELOFIBROSIS PATIENTS

    READ MORE

    STUDY LINKS ESAS TO HIGHER LEUKEMIA RISK FOR SOME

    By Donna Young Washington Editor Erythropoiesis-stimulating agents (ESAs), such as Aranesp, Epogen and Procrit, may increase the risk of acute leukemia in patients with a certain bone marrow disorder, researchers reported at the American Society of Hematology’s annual meeting in Atlanta. In a retrospective study examining 30 years of records of 311 patients with myelofibrosis,… Read More »STUDY LINKS ESAS TO HIGHER LEUKEMIA RISK FOR SOME

    READ MORE

    GLEEVEC(R) APPROVED IN THE US FOR FIVE RARE LIFE-THREATENING DISORDERS WITH LIMITED TREATMENT OPTIONS

    Thursday October 19, 7:25 pm ET Approvals Represent First Time a Regulatory Authority has Simultaneously Approved One Targeted Medicine for Five DisordersNow Approved for the Solid Tumor Cancer, Dermatofibrosarcoma ProtuberansUS Approval Also Granted for Treatment of Four Blood Diseases:Multiple Approvals in Only Five Years Highlight new Approach of Developing Treatments Based on Common Molecular Pathways… Read More »GLEEVEC(R) APPROVED IN THE US FOR FIVE RARE LIFE-THREATENING DISORDERS WITH LIMITED TREATMENT OPTIONS

    READ MORE

    1 36 37 38 39
  • Get updates on MPN patients and research breakthroughs.
    What are the latest developments in MPN Research?